Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc

OOTC:ADAPY
0.03
USD
+0.00
(+8.33%)
-0.66EPS
63.53MMarket Cap

Total Valuation

USD

As of June 30, 2025, Adaptimmune Therapeutics plc carries a market capitalization of 63.53M, placing it among publicly traded companies globally. Its enterprise value stands at 86.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap63.53M
Enterprise Value86.15M

Important Dates

Adaptimmune Therapeutics plc's next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of June 30, 2025, Adaptimmune Therapeutics plc has 265.05M shares outstanding.

Shares Outstanding265.05M

Valuation Ratios

These figures are as of June 30, 2025. The price-to-sales ratio is 0.95, and the price-to-book ratio stands at -0.90.

PS Ratio0.95
PB Ratio-0.90
P/TBV Ratio-0.85
P/FCF Ratio-0.32
P/OCF Ratio-0.33

Enterprise Valuation

These figures are as of June 30, 2025. The EV/Sales ratio of 1.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 86.15M versus a market cap of 63.53M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.32

Financial Position

As of June 30, 2025, Adaptimmune Therapeutics plc maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -68.60, indicating conservative leverage, while an interest coverage ratio of -27.11 demonstrates limited ability to service its debt obligations.

Current Ratio1.52
Quick Ratio1.07
Debt / Equity-68.60
Debt / EBITDA-0.32
Interest Coverage-27.11

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -75.06, reflecting losses generated across the asset base. The company generates approximately 132,353.84 in revenue per employee across its workforce of 491.75, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-75.06
Revenue Per Employee132,353.84
Employee Count491.75

Taxes

USD

Over the twelve months ended June 30, 2025, Adaptimmune Therapeutics plc recorded 3.71M in income tax expense. The company reported a pretax loss of -166.04M and -169.76M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax3.71M

Stock Price Statistics

USD

As of the close on November 16, 2026, Adaptimmune Therapeutics plc's stock has declined approximately 7.93% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.02.

52-Week Price Change-7.93%
50-Day Moving Average0.03
200-Day Moving Average0.02

Income Statement

USD

Over the twelve months ended June 30, 2025, Adaptimmune Therapeutics plc generated 65.09M in revenue and converted that into -169.76M in net income, yielding earnings per share of -0.66. EBITDA reached -153.59M, while operating income came in at -145.64M.

Revenue65.09M
Operating Income-145.64M
Pretax Income-166.04M
Net Income-169.76M
EBITDA-153.59M
EBIT-164.22M
Earnings Per Share (EPS)-0.66

Balance Sheet

USD

As of June 30, 2025, Adaptimmune Therapeutics plc holds 26.06M in cash and equivalents against 48.68M in total debt, resulting in a net debt position of -386,000.00. Total book value stands at -70.96M, with working capital of 26.60M providing operational flexibility.

Cash & Cash Equivalents26.06M
Total Debt48.68M
Net Debt-386,000.00
Equity (Book Value)-70.96M
Book Value Per Share-0.27
Working Capital26.60M

Cash Flow

USD

Adaptimmune Therapeutics plc produced -190.03M in operating cash flow over the twelve months ended June 30, 2025. After subtracting -2.89M in capital expenditures, free cash flow totaled -192.91M - equivalent to -0.75 per share.

Operating Cash Flow-190.03M
Capital Expenditures-2.89M
Free Cash Flow-192.91M
FCF Per Share-0.75

Margins

These figures cover the twelve months ended June 30, 2025. The operating margin of -223.76 and net profit margin of -260.82 provide insight into operational efficiency.

Operating Margin-223.76
Pretax Margin-255.12
Profit Margin-260.82
EBITDA Margin-235.99

Dividends & Yields

These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -311.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.10, meaning Adaptimmune Therapeutics plc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-2.10
FCF Yield-311.69

Scores

As of June 30, 2025, Adaptimmune Therapeutics plc has an Altman Z-Score of -15.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-15.77